Merck-Medco consent injunction in California pharmacy suit follows FTC formula for Lilly/PCS.
MEDCO CONSENT INJUNCTION IN CALIF. PHARMACY SUIT FOLLOWS FTC formula in the Lilly/PCS consent agreement signed late last year. To end the pharmacy litigation in California, Merck-Medco is agreeing to make an open formulary available to all of its current and prospective customers. The agreement was confirmed in a Feb. 22 consent injunction in Bacon-Normandi v. Merck, signed before Oakland federal judge D. Lowell Jensen. The case was scheduled to go to trial on Feb. 21.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth